HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

SGLT-2 inhibition in IgA nephropathy: the new standard of care?

Abstract
Despite supportive measures that slow the rate of progression of chronic kidney disease in IgA nephropathy, many patients still progress to end-stage kidney disease. Currently employed immunosuppressive strategies lack conclusive efficacy data, while there is evidence for treatment-emergent toxicity. A subanalysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease Trial, which encompassed 270 patients with a diagnosis of IgA nephropathy, now provides early evidence that dapagliflozin may be a safe and effective addition to current standard of care in IgA nephropathy.
AuthorsJonathan Barratt, Jürgen Floege
JournalKidney international (Kidney Int) Vol. 100 Issue 1 Pg. 24-26 (07 2021) ISSN: 1523-1755 [Electronic] United States
PMID33878337 (Publication Type: Journal Article, Comment)
CopyrightCopyright © 2021 International Society of Nephrology. All rights reserved.
Chemical References
  • Benzhydryl Compounds
  • Glucosides
  • Immunosuppressive Agents
  • dapagliflozin
Topics
  • Benzhydryl Compounds
  • Glomerulonephritis, IGA (drug therapy)
  • Glucosides
  • Humans
  • Immunosuppressive Agents (adverse effects)
  • Kidney
  • Renal Insufficiency, Chronic
  • Standard of Care

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: